THE![](https://www.amrer.it/img/biotecnologici-e-biosimilari.jpg)
The document concerns the appropriate use of biosimilar drugs in the treatment of rheumatic diseases. It was elaborated by 13 regional Rheumatology Centers and by Amrer (Association of Rheumatic Patients). In Emilia Romagna there are about 32,000 people with active exemption for rheumatic disease and over 500 pediatric cases. THE POSITION PAPER
![](https://www.amrer.it/img/biotecnologici-e-biosimilari.jpg)
…
(… continues)
taken from quotidianosanità – 06 luglio 2015